Alloy Therapeutics, Inc.

Industry

  • Biotechnology
    • Transgenics
    • Drug Discovery Technologies
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
  • Services
See more in Biomedtracker

Latest on Alloy Therapeutics, Inc.

Scrip

Deal Watch: Oak Hill Picks Up Where Roche Left Off In Angelman Syndrome

 
• By Joseph Haas

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Oak Hill Licenses Roche’s Rugonersen,

Scrip

Deal Watch: FTC Keeps Current Merger Guidelines In Place, For Now

 
• By Joseph Haas

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Trump Appointee Ferguson Keeps Biden-E

Scrip

Deal Watch: Lilly Looks To Alchemab’s ‘Resilient’ Antibodies To Take On ALS

 
• By Joseph Haas and Jung Won Shin

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Lilly Partners With UK’s Alchemab On A

Scrip

Asia Deal Watch: Otsuka Lands Second Alliance With Ionis, Focused On ALS Subpopulation

 
• By Joseph Haas, Jung Won Shin, and Lisa Takagi

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Otsuka Pays $10m Up Front For Ion